We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Medexus Pharmaceuticals Inc | TSX:MDP | Toronto | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.04 | -2.52% | 1.55 | 1.55 | 1.59 | 1.62 | 1.52 | 1.61 | 37,687 | 20:59:58 |
From Jun 2021 to Jun 2024
TORONTO, May 26, 2022 /CNW/ - Ken D'Entremont, Chief Executive Officer, Medexus Pharmaceuticals (Medexus) (TSX: MDP) shares his Company's story in an interview with TMX Group.
The View From The C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange. Videos provide insight into how company executives think in the current business environment. To see the latest View From The C-Suite visit https://www.tmxmoney.com/en/csuite.html.
About Medexus Pharmaceuticals, (TSX: MDP)
Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform and a portfolio of proven best-in-class products. Their current focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy. They continue to build a highly differentiated company with a growing portfolio of innovative and high-value orphan and rare disease products that will underpin their growth for the next decade.
SOURCE Toronto Stock Exchange
Copyright 2022 Canada NewsWire
1 Year Medexus Pharmaceuticals Chart |
1 Month Medexus Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
